<DOC>
	<DOCNO>NCT01151137</DOCNO>
	<brief_summary>Primary Objective : - Demonstrate efficacy Dronedarone prevent major cardiovascular event ( stroke , systemic arterial embolism , myocardial infarction cardiovascular death ) unplanned cardiovascular hospitalization death cause patient permanent Atrial Fibrillation [ AF ] additional risk factor Secondary Objective : - Demonstrate efficacy Dronedarone prevent cardiovascular death This event-driven study common study end date [ CSED ] determine Steering Committee base number event ( stroke , systemic arterial embolism , myocardial infarction cardiovascular death ) .</brief_summary>
	<brief_title>Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone Top Standard Therapy</brief_title>
	<detailed_description>The study period per participant variable depend enrollment study . A final follow-up visit occur within 1 month CSED .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : Permanent AF define presence follow criterion : Availability one 12lead ECG 14 day prior randomization show patient AF atrial flutter ; Availability documentation ( include either rhythm strip medical report rhythm ) show patient AF atrial flutter least 6 month prior randomization ; No evidence sinus rhythm period two documentation AF ; Decision patient physician allow AF continue without effort restore sinus rhythm . At least one follow risk criterion : Coronary artery disease ; Prior stroke Transient Ischemic Attack [ TIA ] ; Symptomatic heart failure ; Left ventricular ejection fraction [ LVEF ] less equal 0.40 ; Peripheral arterial occlusive disease ; Aged 75 year old hypertension diabetes mellitus . Exclusion criterion : Paroxysmal AF ; Persistent AF without decision allow AF continue without effort restore sinus rhythm ; Heart failure NewYork Heart Association [ NYHA ] class IV recent unstable NYHA class III . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>